Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Financial Times: Analysts say Pfizer moving too slow on M&A

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Mar 04, 2023 2:47pm

116 Views

Post# 35319395

RE:Financial Times: Analysts say Pfizer moving too slow on M&A

As we learned on yesterday's call, the PFE 90 day exclusivity has expired, and Bracelet-1 data is now being shared with 'quite a few' other BP's. While it was also confirmed that PFE remained 'interested', it seems counterproductive to me that Pfizer would allow for a bidding war to commence, instead of just offering up a fair acquisition price.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec